With the treatment landscape for HER2-positive metastatic breast cancer rapidly changing, the authors of the DESTINY-Breast01 study wanted to make the results of this study accessible and understandable for patients. By publishing the article ‘Trastuzumab deruxtecan in previously treated HER2-positive metastatic breast cancer: Plain language summary of the DESTINY-Breast01 study’ in Future Oncology, they’ve been able to provide a visual, lay language summary of the study that is citable, accessible and, more importantly, discoverable.
Read the PLSP in full here.
The original article, entitled ‘Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer’, published in New England Journal of Medicine, can be found here.